Studies
A Phase 2 Study of Donor-Derived Multi-Tumor-Associated Antigen-Specific T Cells (MT-401) Administered to Patients with Acute Myeloid Leukemia (AML) following Hematopoietic Stem Cell Transplantation (ARTEMIS)
Cancer
Internal Medicine
Leukemia
Adult Subjects
Female Subjects
Male Subjects
This study is a Phase 2 multicenter study with a Safety Lead-in evaluating safety and efficacy of MT-401 administration to patients with AML, who have received their first allogeneic HSCT. The dose administered is 50 x 10^6 cells (flat dosing).
Protocol for a research sample repository for allogeneic hematopoietic stem cell transplantation, other cellular therapies and Marrow Toxic Injuries
Cancer
Internal Medicine
Pediatric Subjects
Adult Subjects
Female Subjects
Male Subjects